Convection enhanced delivery of Rhenium (186Re) Obisbemeda (186RNL) in recurrent glioma: a multicenter, single arm, phase 1 clinical trial

Andrew J. Brenner (), Toral Patel, Ande Bao, William T. Phillips, Joel E. Michalek, Michael Youssef, Jeffrey S. Weinberg, Carlos Kamiya Matsuoka, Marc H. Hedrick, Norman LaFrance, Melissa Moore and John R. Floyd
Additional contact information
Andrew J. Brenner: Mays Cancer Center at UT Health San Antonio
Toral Patel: UT Southwestern Medical Center of Dallas
Ande Bao: Case Western Reserve University
William T. Phillips: Mays Cancer Center at UT Health San Antonio
Joel E. Michalek: Mays Cancer Center at UT Health San Antonio
Michael Youssef: UT Southwestern Medical Center of Dallas
Jeffrey S. Weinberg: University of Texas MD Anderson Cancer Center
Carlos Kamiya Matsuoka: University of Texas MD Anderson Cancer Center
Marc H. Hedrick: Plus Therapeutics
Norman LaFrance: Plus Therapeutics
Melissa Moore: Plus Therapeutics
John R. Floyd: Mays Cancer Center at UT Health San Antonio

Nature Communications, 2025, vol. 16, issue 1, 1-12

Abstract: Abstract Rhenium (186Re) Obisbemeda (186RNL), chelated-186Re encapsulated in nanoliposomes and delivered to brain tumors via convection enhanced delivery (CED), was evaluated in a Phase 1 dose escalation trial (NCT01906385). The primary objective was to determine the maximum tolerated dose (MTD). Secondary objectives included safety and tolerability, dose distribution, the overall response rate (ORR), disease-specific progression-free survival (PFS), and overall survival (OS). 21 patients received up to 22.3 mCi 186RNL over 6 dosing cohorts. Most adverse events (AEs) were unrelated to 186RNL and the MTD was not reached. Although not predefined outcomes, the mOS and mPFS were 11 and 4 months, respectively, and found to correlate with radiation absorbed dose to the tumor and percent tumor treated. When dichotomized by absorbed dose of 100 Gy, the mOS and mPFS were 17 months and 6 months, respectively, for >100 Gy, compared to 6 (mOS) and 2 (mPFS) months, respectively, for

Date: 2025
References: Add references at CitEc
Citations:

Downloads: (external link)
https://www.nature.com/articles/s41467-025-57263-1 Abstract (text/html)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:nat:natcom:v:16:y:2025:i:1:d:10.1038_s41467-025-57263-1

Ordering information: This journal article can be ordered from
https://www.nature.com/ncomms/

DOI: 10.1038/s41467-025-57263-1

Access Statistics for this article

Nature Communications is currently edited by Nathalie Le Bot, Enda Bergin and Fiona Gillespie

More articles in Nature Communications from Nature
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().